CLINICAL & PIPELINE·Drug Approval
Gilead's SUNLENCA (Lenacapavir Sodium) Secures Key Efficacy and Manufacturing Approvals, Bolstering Market Position
Gilead Sciences Inc. secured a significant Efficacy supplement approval for SUNLENCA (lenacapavir sodium) on November 25, 2024, following its initial New Molecular Entity approval in December 2022. This, coupled with a November 13, 2024, Manufacturing (CMC) approval, underscores Gilead's commitment to expanding the drug's utility and ensuring robust supply. Decision-makers must assess the implications for competitive landscapes and supply chain resilience.
90-Day Activity